In conclusion, we demonstrated the inhibitory effects of CDDO-Im on triple-negative breast cancer with a potential to target cancer stem cell subpopulation, as evidenced by inhibition of CD44+/CD24−/low/EpCAM+ cells and tumorsphere formation. The gene discussed is EPCAM; the disease is triple-negative breast carcinoma.